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Anatomy of the Intervertebral Disc
 he Human Intervertebral Disc (IVD) is a ibrocartilagenous 
structure positioned between each connecting vertebra of the spinal 
column. Mechanically, the IVD transmits load, arising from body 
weight and muscle activity, and permits a range of spinal movement 
including bending, lexion and torsion [1]. he normal IVD is 
composed of three morphologically distinct regions: the 
Cartilaginous End Plates (CEP), the highly organised Annulus 
Fibrosus (AF) and the central gelatinous Nucleus Pulposus (NP), 
which operate collectively to mechanically transfer loads and disperse 
energy evenly throughout the spine. he CEP is a layer of hyaline 
cartilage which separates the AF and NP from the adjacent vertebral 
body and facilitates difusion of nutrients and oxygen to the avascular 
internal structures of the IVD [2,3]. he AF can be further subdivided 
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into the outer and the inner AF. he outer AF contains large amounts 
of ibrous collagen type I orientated into lamellae, providing resistance 
to tensile forces from bending and twisting of the vertebral column 
[4]. he inner AF is a transition zone between the randomly 
organised, hydrated NP and the highly organised, ibrous outer AF, 
with characteristics of both tissue types observed in this region. he 
NP has a gelatinous matrix composed of randomly arranged collagen 
type II ibres, radially arranged elastin ibres and small amounts 
of collagen types VI, IX and XI, all of which are embedded in a 
highly hydrated matrix rich in proteoglycans (mainly aggrecan) [5]. 
he hydrated proteoglycans provide viscoelasticity and resistance to 
compression whilst the collagen crosslinks confer tensile strength [6].
Cell Types Present in the Normal IVD
 he cells which reside in the NP and AF are morphologically 
and phenotypically distinct. At maturity the AF contains elongated 
ibroblast like cells at a cell density of approximately 9 x 106 cells/ cm3 
[7]. At birth NP cells display large (25-85 µm) vacuolated morphology 
with distinct resemblance to the embryonic notochordal cells from 
which they are assumed to originate [8-10]. During maturation the 
population of large vacuolated cells within the NP decreases and 
becomes replaced by smaller, round and non-vacuolated chondrocyte 
like cells at a cell density of approximately 4 x 106 cells/ cm3 [7,10,11]. 
he origin of these smaller chondrocyte like cells in the NP is 
currently an unresolved area of IVD research with controversy as to 
whether the chondrocyte like cells migrate from surrounding tissues 
or diferentiate from the notochordal cells [12,13]. Furthermore a 
deinitive phenotypic maker of NP cells is yet to be characterised, thus 
the origin and proile of these cells remains a signiicant challenge for 
cell based regenerative strategies [14-18]. 
Degeneration of the IVD
 Degeneration of the IVD is characterised by progressive changes 
in the Extracellular Matrix (ECM) due to altered cell metabolism, 
matrix synthesis and an increase in degradation of normal matrix 
components [19,20]. As IVD degeneration advances collagen type II 
in the NP is gradually replaced by the more ibrous collagen type I 
[7]. he overall proteoglycan composition of the NP is reduced and 
altered by decreased synthesis of aggrecan and increased synthesis 
of versican, decorin and biglycan, thus resulting in reduced water 
bibing capacity and a consequential decreased hydration of the 
extracellular matrix within the NP [21,22]. Concurrently matrix 
degradation is accelerated by the upregulation of MMPs (Matrix 
Metallinoproteinases) and ADAMTS (A Disintegrin And 
Metalloproteinase With hrombospondin Motifs) [23,24]. 
Compositional changes in the matrix during IVD degeneration is also 
accompanied by cellular changes with increased apoptosis [25,26] and 
senescence [19,27,28] displayed by NP cells, together with decreased 
tissue cellularity and viability of remaining disc cells [19,29]. 
 he cells of the IVD produce a plethora of catabolic cytokines and 
chemokines [30-40] with highest expression seen in the NP and inner 
AF [30,33], expression within the outer AF is diferentially expressed, 
with posterior AF tissue displaying higher expression of cytokines 
than the anterior AF [38]. here is increasing evidence supporting the 
role of a pivotal cytokine: Interleukin (IL)-1 in the pathogenesis of 
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IVD degeneration [30,31,33,41-45]. With an increase in the 
production of the IL-1 agonists (IL-1α and IL-1β) and their active 
receptor IL-1RI, without a concordant increase in the natural 
inhibitors: IL-1 Receptor antagonist (IL-1Ra) or the decoy receptor: 
IL-1RII; within the cells of the NP and inner AF [33]. IL-1 has been 
shown to induce a plethora of catabolic events, which are linked to 
degradation of matrix [33,42], neuronal ingrowth and blood vessel 
ingrowth into the normally aneural and avascular disc [41,46]. 
Inhibition of IL-1 in IVD tissue in vitro has been shown to 
completely abrogate matrix degradation [42] whilst inhibition of 
TNF alpha had no such efect [42]. he importance of IL-1 in the 
pathogenesis of disc degeneration was furthered by the observation 
that spontaneous IVD degeneration occurred in a knockout mouse 
model where the natural inhibitor of IL-1 (IL-1Ra) was removed [47], 
which is further supported by the indings that polymorphisms in the 
IL-1 gene cluster increases the risk of IVD degeneration and low back 
pain [48-51]. hese cellular changes during IVD degeneration lead to 
increased production of cytokines, matrix degrading enzymes, and 
leads to angiogenesis and nerve ingrowth which lead to sensitization 
of local nerves and painful stimuli. In addition release of cytokines 
from the degenerate disc, particularly following herniation leads to 
damage to the local nerve root, facet joints and adjacent vertebrae.
 he cell mediated imbalance between normal matrix synthesis and 
degradation collectively results in a loss in the structural integrity of 
the NP with reduced hydration, reduced osmotic swelling pressure 
and overall reduced disc height [52]. his results in a diminished 
ability to withstand load and asymmetric distribution of 
compressive forces which leads to the formation of tears and issures 
through the AF, increasing the risk of disc herniation and providing 
an access route for the ingrowth of nerves and blood vessels associated 
with the sensation of chronic low back pain [41].
Current Treatments for Degenerative Disc Disease
 Current practises for the treatment of low back pain are 
directed towards alleviating patient symptoms by conservative 
treatments including pain management, lifestyle adjustments and 
rehabilitation programs or surgical procedures to stabilise or remove 
the damaged tissue including discectomy and spinal fusion [53]. 
Despite this, these treatments are oten associated with altered spine 
biomechanics and accelerated degenerative changes in adjacent 
discs [54,55]. Emerging treatments, driven by scientiic research, 
have aimed to develop a biological approach which addresses the 
underlying pathogenesis of IVD degeneration. Many studies have 
explored the use of protein delivery to inhibit catabolic factors, 
promote matrix synthesis or reduce inlammation [32,56-59]. Despite 
this, the use of growth factors alone fails to treat the dysfunctional 
NP cells which display increased expression of catabolic factors [37], 
decreased synthesis of matrix components and increased senescence 
[19,27,28], thus driving degeneration.
 Consequently, a vast amount of research has focused on the use 
of cells, either alone, or together with biomaterial scafolds, in order 
to repopulate the NP and simultaneously regenerate the matrix 
(Table 1). From a clinical perspective the aim is to restore/maintain 
spine biomechanics and alleviate patient symptoms, thus the use of 
cells in combination with a biomaterial scafold to regenerate the 
matrix whilst restoring disc height appears to be an attractive 
strategy. Counter to this argument however is whether the 
regenerative capacity of cells is necessary or just an added 
complication, particularly for regulatory approval. Recent progress in 
tissue engineering has produced a magnitude of biomaterial scafolds 
with improving resemblance both structurally and mechanically to 
the native NP, thus the development of a non-degradable biomaterial 
which mimics the functional biological matrix enough to provide the 
correct biomechanics may render the use of cells unnecessary. his 
review discusses the potential future treatment strategies of IVD 
degeneration including the use of cells or biomaterials, used 
individually or in combination, in order to answer the question: what 
is the ideal strategy for IVD regeneration?
Cells Alone for Disc Degeneration
 he choice of cells to be used in IVD regeneration must be 
carefully considered to ensure successful therapeutic outcome. he 
implanted cells would need to meet certain requirements for adoption 
into clinical practice: they should be easily sourced and available in 
suicient numbers to repopulate the NP; cells should be autologous 
where possible to minimise immunogenic risk and be capable of 
regenerating the correct biological matrix in order to functionally 
replicate disc metabolism and biomechanics [75]. he safety, 
efectiveness and viability of the cells must also be thoroughly 
characterised within the hypoxic and acidic disc microenvironment.
 he use of autologous NP cells would be the ideal strategy 
and a variety of studies have shown them to be successful; both 
biologically to regenerate the NP matrix and clinically to reduce 
pain [76-78,]. Transplanted disc derived chondrocytes injected into 
degenerated IVDs of dogs were found to maintain retention of disc 
height and promote proteoglycan and collagen type II deposition [76]. 
Furthermore patients treated with autologous disc cell transplantation 
following discectomy, as part of the Euro Disc Randomised Trial, 
reported pain reduction ater two years, in comparison to patients who 
did not receive autologous disc cell transplantation [76]; however, due 
to a lack of follow up on these patients, the long term efectiveness 
of this treatment cannot be accurately assessed. Furthermore, due to 
the low NP tissue cellularity, the harvesting of NP cells from more 
than one disc or in vitro expansion of cells for several weeks would be 
required to obtain a suicient number of viable cells for 
transplantation. he use of autologous NP cells extracted from 
degenerate discs may also be inappropriate for regenerative purposes 
due to the increased expression of catabolic factors [37], decreased 
synthesis of normal matrix components and increased senescence 
displayed by these cells [19]. Finally the needle puncture which is 
currently used to extract autologous NP cells, has been shown 
to accelerate degenerative changes [79-81]. Non-autologous cell 
sources such as notochordal cells have also been investigated as 
potential candidates for NP regeneration [82,83]. Recently Potier et 
al., (2014) showed that notochordal cell-rich nucleus pulposus tissue 
stimulates matrix production by bone marrow stromal cells and NP 
cells, combined with increased NP cell proliferation and expression of 
NP phenotypic genes, thus promoting NP regeneration [84]. Despite 
this, the use of notochordal cells raises concerns regarding the 
allogeneic source required [11], the low cellular abundance [85], 
which may be insuicient to accommodate cell transplantation and a 
lack of understanding as to whether notochordal cells can diferentiate 
into a biologically functioning NP cell [86]. 
 Stem cells, particularly human Mesenchymal Stem Cells (hMSC) 
are an attractive cell choice for IVD regeneration since they can be 
extracted from a variety of adult tissues [87], they have proliferative 
capacity, have the ability to diferentiate into multiple cell lineages [88] 
and avoid the ethical issues surrounding the use of embryonic stem 
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Hydrogel Scaffold Material for NP Culture conditions Cellular or Acellular Key Findings Ref
Gelatin hydrogel microspheres In vivo (rabbit) Acellular with platelet-rich 
plasma.
Suppression of degeneration. Proteoglycan 
production in NP and inner AF. 
[60]
Ionic Methacrylated gellan gum- 
(iGG-MA) and photo-crosslinked 
(phGG-MA) hydrogels
In vitro
In vitro and In vivo (subcutaneous rat 
model) 
In vitro and In vivo (subcutaneous)
Acellular and human Inter-
vertebral Disc (hIVD) cells 
encapsulated.
Acellular and ibroblast cells 
(L929 cells) and human 
Intervertebral Disc (hIVD) 
encapsulated hydrogels.
Human bone marrow-derived 
MSCs and nasal chondrocytes
Mechanical properties of cell-laden hydrogels 
increased in comparison to acellular hydrogels. 
Encapsulated cells found to be viable up to 21 
days of culturing. In vivo a thin ibrous capsule 
was observed around implanted hydrogels. No 
evidence of necrosis, calciication, and acute 
inlammatory reaction.
Apoptosis observed in phGG-MA.
Evidence of chondrogenesis following subcuta-




Atelocollagen® gel In vivo: Rabbit. Rabbit MSCs Degenerated discs of MSC-transplanted group 
regained a disc height value of about 91% 
compared to normal controls. Proteoglycan 
production conirmed by histological and immu-
nological evaluation.
[64]
Alginate In vitro under hypoxia (2%) and normoxia 
(20%)
Rat MSCs with transforming 
growth factor-β1
Hypoxia induced upregulation of Glucose 
transporter-3, matrix metalloproteinase-2, 
collagen type II and type XI, and aggrecan 
mRNA and protein expression was upregu-
lated, Transforming growth factor-β treatment 
increased MAPK activity and Sox-9, aggrecan, 
and collagen type II gene expression.
[65]
Photocrosslinked alginate In vitro and In vivo (murine subcutaneous 
model)
Bovine NP cells Production of aggrecan and collagen type II. 
Cellular hydrogels were mechanically superior 
to acellular hydrogels.
Young’s modulus of cellular hydrogels signiif-
cantly increased from 4 to 8 weeks.
[66]
Type II collagen and Hyaluronic 
Acid (HA).
In vitro Rat MScs with and without 
differentiating medium.
Increased aggrecan and collagen type II with 
decreased collagen I in hydrogel constructs 
where differentiating medium used.
[67]
Hyaluronan gel (Durolane®), hydro-
gel (Puramatrix®), and tissue-glue 
gel (TISSEEL®)
In vivo mini pigs human Mesenchymal Cells 
(hMSCs), IVD cells (hDCs), 
and Chondrocytes (hCs)
Xenotransplanted hMSCs and hCs survived 
in porcine IVDs for 6 months and produced 
collagen II in all six animals. 
Following six months pronounced endplate 
changes, and bone mineralisation indicating 
severe IVD degeneration were observed within 





In vitro Human MSCs in standard 
medium.
Production of proteoglycans and collagens in a 
ratio which more closely resembles that of NP 









medium alone and with the 
supplementation of transform-
ing growth factor β1 or Growth 
and Differentiation Factor 5 
(GDF-5)
All HA, HA-pNIPAM and their degradation 
products were cytocompatible to NP cells.
Glycosaminoglycan synthesis was similar in 
HA-pNIPAM and alginate gels.
Higher expression of hyaluronan synthases 
and lower expression of COLI and COLII 
mRNA were noted in cells cultured in HA-pNI-
PAM.
Higher GAG/DNA ratio and higher collagen 
type II, SOX9, cytokeratin-19, cluster of 
differentiation 24, and forkhead box protein F1 
expressions were found for hMSCs cultured 
in HA-pNIPAM compared with those cultured 
in alginate.
Ex vivo, direct combination of HA-pNIPAM with 
the disc environment induced a stronger disc-
like differentiation of hMSCs than predifferen-





grafted with Polyamidoamine 
(PAA))
In vitro hMSC with standard and 
chondrogenic differentiating 
medium.
Elevated expression levels of aggrecan and 
collagen II when cultured in chondrogenic 
media under hypoxic conditions, in comparison 
with culture in hMSC media for 14 days.
Signiicant decrease in stiffness and modulus 
values of cellular hydrogels in comparison with 
acellular hydrogels at both day 7 and day 14.
Increasing cytoxicity with increasing UV 
exposure time. 
[72]
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cells. A number of hMSC sources have been investigated including 
bone marrow, periosteum, synovial membrane and adipose tissue 
[89-91]. Studies have suggested that the source of MSCs are critical 
to the clinical outcome with improved expansive and chrondrogenic 
diferentiation potential for cartilage repair in synovial membrane and 
adipose tissue derived MSCs in comparison to bone marrow derived 
MSCs [87-92]. Recently patient matched bone marrow derived and 
adipose derived MSCs were compared to determine their 
diferentiation capacity towards NP cells following stimulation with 
the growth factor GDF-6, which demonstrated adipose derived MSCs 
displayed micromechanical properties more akin to the NP than the 
bone marrow derived MSCs suggesting these cells may be more suited 
to NP regeneration [93].
 Increasing evidence has shown that hMSC are able to 
diferentiate into NP like cells and produce a biologically functional 
NP matrix consisting of proteoglycans and collagen type II [94-97]. 
Studies have also shown that co-culture of hMSCs and NP cells not 
only enhances NP cell diferentiation, but also restores normal NP cell 
function and increases NP cell proliferation, thus aiding the repair 
process [98-100]. Despite limited publications on the use of MSCs 
alone for the regeneration of the IVD, successful outcomes have been 
reported, particularly in small animal models where transplanted 
bone marrow derived MSCs have been shown to undergo 
chondrogenesis with consequential deposition of proteoglycans and 
collagen type II in both rabbit IVD [97] and rat coccygeal discs [101]. 
Similarly expression of discogenic genes with matrix staining for 
aggrecan and collagen type II occurred where hMSCs were injected 
into an explant NP tissue model [102].
 he success of hMSCs alone for the regeneration of the IVD in 
small animal models, has not always been replicated in large animal 
models. Henriksson et al., (2009) investigated the survival and 
diferential capacity of hMSCs into injured porcine discs both alone 
and with a hydrogel carrier [103]. hMSCs were shown to survive 
and express typical chondrogenic markers, but immunopositivity for 
aggrecan and collagen type II was only observed in cell/hydrogel 
discs. Furthermore, low cell survival and the formation of a collagen 
type I/II scar tissue has been reported following 3 months ater 
in vivo injection of allogenic disc derived MSCs [104]. Collectively 
these results suggest that transplantation of cells alone into a large 
animal model is not suicient to produce the correct functional 
matrix, possibly due to the larger disc size giving a greater nutrient 
difusion distance, inducing nutrient deprivation for the 
transplanted cells. Furthermore concerns, regarding MSC leakage 
following injection, with consequential undesirable bone formation, 
has been demonstrated as a potential side-efect of this therapeutic 
strategy, thus highlighting the potential need for cell carrier systems 
or annulus-sealing technologies to avoid the pitfalls of this treatment 
approach [105]. Despite this, results from a small human trial, 
whereby 10 patients with disc degeneration but intact annulus 
ibrosus, received an injection of autologous expanded bone marrow 
derived MSCs, reported signiicant improvements in pain and 
disability 12 months following treatment [96]. However these patients 
demonstrated no evidence of improved disc height [86]. hese results 
suggest that the use of hMSCs transplanted into the IVD alone has 
limitations but may be improved with the use of an appropriate 
biomaterial scafold.
 he major drawback of MSC based strategies is a lack of 
understanding of the normal NP cell phenotype. he majority of 
studies, including those which have been discussed in this review, 
deine NP cell diferentiation using traditional chondrogenic genes 
such as Sex Determining Region (SRY) box 9, collagen type II and 
aggrecan [94,102,106,107]. However cells and tissues of articular 
cartilage and NP demonstrate signiicant diferences in terms of 
morphology, ECM disposition and biomechanical behaviour [5]; 
consequently, the identiication of diferential NP markers which can 
be used to inform and thoroughly assess MSC diferentiation is the 
current focus of many research studies [14-18,108].
Acellular Biomaterials for Disc Degeneration
 Acellular biomaterial scafolds provide a more simplistic 
therapeutic alternative to cellular strategies without the added 
complications of cell harvesting. Similar to cellular strategies, an 
increasingly prevalent issue with acellular strategies is whether one 
acellular treatment will accommodate all stages of degeneration. 
Based on trends in current research, one design strategy for 
acellular treatments could include non-invasive injectable 
monophasic hydrogels combined with inhibitors of degeneration or 
growth factors during early stages of degeneration to repair the NP 
[60], injectable biphasic scafolds to repair the NP and AF in mid 
stages of degeneration and Tissue Engineered Total Disc 
Replacements (TE-TDR) in severely degenerate cases [109].
 he use of hydrogels as delivery systems of catabolic inhibitors and 
growth factors to provide an acellular treatment strategy for NP repair 
has been successfully reported [60,110-112]. It must be noted however 
that a recent focus on the use of hydrogels as delivery systems for both 
cells and biomolecules is evident, thus the efectiveness of catabolic 
inhibitors and/or growth factors alone within monophasic scafolds 
to repair the NP has not been thoroughly assessed. here is a clear 
rationale for this however since a regenerative source would need to 
be combined with mediators to inhibit degeneration to fully restore 
normal disc function.
 he main challenge in the development of monophasic acellular 
hydrogels for the treatment of IVD regeneration is ensuring suicient 
mechanical properties to withstand the load forces exerted on the 
spinal column. Silva-Correia et al., (2013) investigated the 
mechanical properties of acellular and cell laden ionic- and 
photo-crosslinked methacrylated gellan gum hydrogels; mechanical 
integrity of acellular hydrogels was maintained throughout the 21 
day culture period, however cell-laden hydrogels were mechanically 
superior [61].
Chitosan/Gelatin/β-Glycerol 
Phosphate (C/G/GP) disodium salt 
hydrogels
In vitro Rabbit NP cells. Increased gene expression of aggrecan and 
type II collagen and increased glycosamino-
glycan production in NP cells cultured in the 
hydrogel in comparision to monolayer controls.
[73]
Gelatin/chitosan/glycerol phos-
phate hydrogel with ferulic acid.
In vitro Rabbit NP cells Up-regulation of MMP-3 and up-regulation 
aggrecan and type II collagen in mRNA level.
The sulfated-glycosaminoglycan production 
was increased and the apoptosis was inhibited 
in the post-treatment group.
[74]
Table 1: Hydrogels used for NP regeneration.
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 Total Disc Replacement (TDR), which consists of polyethylene 
on metal, or metal on metal implants engineered to resemble a low 
friction ball and socket joint, is currently considered as an alternative 
treatment strategy to spinal fusion [113]. his method does not 
avoid invasive surgery since the excision of the degenerate disc is 
unavoidable, however does restore some mobility to the intervertebral 
joint which could reduce the risk of adjacent disc degeneration [114]. 
Considerable debate as to whether TDR is more eicacious than 
spinal fusion still remains. A Cochrane review [114] systematically 
assessed the eicacy outcomes of TDR in terms of motion 
preservation, adjacent disc degeneration and patient satisfaction and 
concluded that no evidence of superior clinical outcomes between 
TDR and spinal fusion was observed. Furthermore the authors of 
this review advised that caution should be taken when considering 
the adoption of TDR into wide scale clinical practice since the 
efectiveness of TDR is patient dependent and complications may 
arise years following treatment [114]. Despite this, Siepe et al., (2010) 
conducted a 5-10 year follow up of patients whom had undergone 
TDR as treatment for disc degeneration and concluded that TDR 
were a viable treatment alternative to spinal fusion [115]. It is clear 
that both spinal fusion and TDR have limitations, however the 
development of novel polymeric implants which replicate the 
biomechanics of the natural disc could be considered as an efective 
acellular strategy, particularly in severe stages of degeneration, 
where the use of monophasic biomaterials or cells alone would be 
insuicient to provide the biological functions of all anatomical 
regions of the IVD. In particular novel viscoelastic TDR materials have 
been developed which replicate the lexibility, stifness and stress/stain 
dynamics of native disc, thus could be used as a more mechanically 
eicacious implant material for TDR in the future [109,116].
 Despite the development of novel polymeric materials which could 
be used as a single material implant for TDR, more efective outcomes 
may be achieved with a Tissue Engineered (TE) strategy, including 
a combination of biomaterials in order to efectively replicate the 
total IVD (NP, AF, CEP). To date, biphasic scafolds, seeded with 
cells, have shown potential for regeneration of two of the anatomical 
regions of the IVD (NP and AF) [117,118]. Furthermore, calcium 
polyphosphate substrates have been used to engineer cartilaginous 
end plates [119,120]. he success of combining multiple 
biomaterials as an efective acellular strategy is dependent on 
replicating the correct biomechanical properties of the NP, AF and 
CEP. A TE-TDR which replicates all three anatomical regions is yet to 
be developed, however the studies discussed here demonstrate clear 
progression in the aim to develop a functional spinal unit.
Cellular Biomaterials for Disc Degeneration
 As discussed, the use of cells alone or acellular biomaterials for 
disc repair, individually have shown some success for the treatment 
of IVD degeneration, both, however provide diferent clinical 
outcomes, such as the regenerative capacity provided by the use of 
cells and the mechanical support provided by acellular biomaterial 
scafolds; consequently current research has focused on the use of 
cellular biomaterial scafolds (Table 1) which provide biomechanical 
support whilst simultaneously regenerating the NP matrix, thus 
resulting in an integrated and biologically functioning tissue. he ideal 
load bearing biomaterial scafold for IVD regeneration, which meets 
all requirements in terms of biocompatibility, bioactivity, mechanical 
properties and injectability, is yet to be produced. However a 
limited number of studies have demonstrated success in terms of 
hMSC encapsulation and diferentiation towards the NP lineage. 
Traditionally the biocompatability of natural polymer scafolds has 
been an appealing choice for NP repair, including collagen [121], 
alginate [65], gelatine [60], hylauronan [67,68], chitosan-glycerophos-
phate [94,107] and thermoresponsive hyaluronic acid (Table 1) [71]. 
However the use of natural polymers raises concerns regarding batch 
variation and immunogenic risk; consequently a number of studies 
have looked to develop synthetic polymer scafolds which have the 
added advantage of synthesis control, large scale production and the 
ability to tailor bioactivity, mechanical properties and degradation 
rates. However toxic chemicals including initiators, stabilisers, 
organic solvents, cross linkers, emulsiiers and unreacted monomers 
which may be used in the synthesis and polymerisation of synthetic 
hydrogels pose a signiicant safety risk [64,122]. An ideal 
biomaterial scafold, particularly in early stages of degeneration when 
it may not be necessary to excise the degenerate disc, would be an 
injectable hydrogel which delivers cells and biomolecules followed by 
in situ solidiication; however this again poses signiicant challenges 
since potentially toxic unreacted material may need to be injected 
directly into the body, for this reason a variety of hydrogel systems 
with diferent fabrication techniques have been investigated [122]. 
Encapsulation and subsequent discogenic diferentiation of MSCs 
has been performed in synthetic photo-crosslinked hydrogels, 
however apoptosis [63] and cytotoxicity with increasing UV exposure 
time [116] has been observed using this fabrication technique; thus 
raising concerns regarding the use of photocrosslinking not only to 
the implanted cells but also to surrounding tissues during delivery 
[72]. An attractive alternative to photo-crosslinked hydrogels is 
the use of thermo-reversible hydrogels which undergo liquid to gel 
transition at body temperature [71,73,123]. Studies have 
demonstrated successful biocompatibility, discogenic diferentiation 
and deposition of an NP like matrix by MSCs cultured in 
thermo-responsive Chitosan-Glycerophosphate (C/Gp) hydrogels 
[94,124]. Further work by Cheng et al., (2013) showed sustained 
release of the antioxidant ferulic acid in thermosensitive 
Chitosan-Gelatin-Glycerol Phosphate hydrogels, with consequential 
reduction in catabolic mediators and increased synthesis of normal 
matrix components, thus could be combined with cells to enhance 
NP regeneration [74]. Alternatively the use of a thermo-reversible 
Hyaluronan-poly(N-Isopropylacrylamide) (HA-pNIPAM) hydrogel 
has been recently shown to induce discogenic diferentiation of MSCs 
with production of an NP like matrix under hypoxic conditions 
[71,70].
 he majority of cellular hydrogel systems have been designed 
for NP regeneration (Table 1) since this is the main region which 
undergoes signiicant cellular and matrix changes during 
degeneration of the IVD [19,20]. Despite this, NP repair is likely to be 
insuicient, particularly in severely degenerate cases where tears in the 
AF may result in extrusion of the implanted biomaterial and/or cells; 
consequently a variety of studies have investigated biphasic scafolds 
which aim to repair the AF and NP simultaneously [118,125,126]. he 
use of electrospinning polymeric material has attracted signiicant 
interest in order to the replicate the highly organised native AF 
structure [127]. Lazebnik et al., (2011) used a biomimetic strategy by 
combining porcine chondrocyte cell seeded agarose gel surrounded 
by cell seeded electrospun polycaprolactine ibres and observed that 
cells were viable, well distributed and orientated themselves in the 
direction of the ibres [128]. Successful incorporation of growth 
factors to enhance regeneration has also been shown in electrospun 
scafolds [129]. Furthermore, biphasic scafolds consisting of a 
hydrogel NP centre surrounded by a polymeric electrospun AF 
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scafold have been shown to possess superior mechanical properties 
[128,130].
 Despite recent success of NP regeneration in vitro and in small 
animal models, there are still signiicant challenges that remain 
before such studies can be scaled up to pre-clinical analysis. 
Unresolved questions include: what is the ideal cell type and source? 
Is the use of a biomaterial scafold necessary? At what stage of 
degeneration is regenerative cell therapy clinically applicable? 
Furthermore, Reitmeir et al., (2014) conducted an in vivo eicacy 
study whereby bone marrow derived MSCS were encapsulated within 
hydrogels, incorporated with anti-angiogenic factors and implanted 
into ovine disc; following 12 weeks no signiicant diference in 
biomechanical properties was observed between implanted and 
untreated discs and disc height and degeneration score deteriorated 
for all implant treated discs [131]. hus caution should be taken 
when considering in vitro results since the complex molecular and 
biomechanical disc microenvironment makes replication of in vitro 
results in vivo extremely diicult. 
Personalized herapies
 he recent advances in quantitative MRI imaging [132] may one 
day enable the clinician to identify early stages of degeneration which 
could be targeted by cell based therapies alone, whilst it is likely mid 
stage degeneration may require cells together with biomaterials. 
However, certain patients may not be suitable for cell based therapies 
and acellular approaches may be more suitable, such as those with end 
plate calciication. With the advent of specialist imaging modalities 
personalised therapies may become possible.
Discussion and Future Outlooks
 When considering the most efective treatment for IVD 
degeneration it is important to deine and diagnose the IVD by 
stage of degeneration. A multitude of hydrogel scafolds for IVD 
degeneration has been proposed each of which is competing to 
provide the ideal therapeutic strategy. It is clear however that one 
scafold will not suice; clinicians should be presented with a variety 
of treatment options, both cellular and acellular, in order deliver the 
most eicacious, safe and cost efective treatment for the stage of 
degeneration. In order to reduce the amount of current surgical 
practise on IVD repair, which at present is clinically counter intuitive, 
scientiic research into IVD degeneration must remain at the forefront 
in order to bridge the gap between research therapeutics and adoption 
into clinical practise.
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